Linezolid Injection

Linezolid Glucose Injection is a synthetically produced oxazolidinone antibiotic that acts as a bacterial protein synthesis inhibitor. It targets the 50S ribosomal subunit of bacteria, preventing the formation of the 70S initiation complex and thereby inhibiting bacterial protein synthesis. This medication is indicated for treating infections caused by Gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) and community-acquired pneumonia (CAP) due to MRSA, as well as complicated skin or skin-and-soft-tissue infections (SSTI), and infections caused by vancomycin-resistant Enterococcus. Notably, it demonstrates excellent safety profiles, making it suitable for use across a wide range of patients—from newborn infants to elderly individuals—and thus enjoys broad clinical application. Linezolid Glucose Injection boasts extensive clinical data and is frequently recommended in treatment guidelines, earning high levels of physician approval.

Category:

Anti-infection products

Return to list

Detailed introduction

The synthetically produced oxazolidinone antibiotic was approved by the U.S. FDA in 2000 for treating infections caused by Gram-positive (G+) cocci, including suspected or confirmed hospital-acquired pneumonia (HAP) due to MRSA. Community-Acquired Pneumonia (CAP), complicated skin or skin-and-soft-tissue infections (SSTI), and vancomycin-resistant enterococcus (VRE) infections.

Linezolid is a bacterial protein synthesis inhibitor that acts on the bacterial 50S subunit. Ribosomal subunit , and it acts most closely at the site of action. Unlike other drugs, linezolid does not affect peptidyl transferase activity; instead, it targets the initiation phase of the translation system, inhibiting the binding of mRNA to the ribosome and preventing the formation of the 70S complex. Initiation complex Its mechanism of action inhibits bacterial protein synthesis. Linezolid uniquely targets and functions in a way that makes it less likely to cross-resist with other antibacterial agents that suppress protein synthesis—whether in Gram-positive bacteria exhibiting intrinsic or acquired resistance traits—and also minimizes the potential for inducing resistance even under in vitro conditions. Bacterial Antibiotic Resistance The emergence of it.

Keywords:

None